[go: up one dir, main page]

MX2009008425A - Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. - Google Patents

Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.

Info

Publication number
MX2009008425A
MX2009008425A MX2009008425A MX2009008425A MX2009008425A MX 2009008425 A MX2009008425 A MX 2009008425A MX 2009008425 A MX2009008425 A MX 2009008425A MX 2009008425 A MX2009008425 A MX 2009008425A MX 2009008425 A MX2009008425 A MX 2009008425A
Authority
MX
Mexico
Prior art keywords
benzenesulfonyl
inhibitors
indole derivatives
ccr9 activity
ccr9
Prior art date
Application number
MX2009008425A
Other languages
English (en)
Inventor
Philipp Lehr
Anthony Winiski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009008425A publication Critical patent/MX2009008425A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1-bencen-sulfonil-1H-indoles, procesos para su producción, y su uso como productos farmacéuticos, por ejemplo, en el tratamiento de los trastornos que son mediados por CCR9, tales como, por ejemplo, enfermedad inflamatoria del intestino.
MX2009008425A 2007-02-06 2008-02-04 Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. MX2009008425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101784 2007-02-06
PCT/EP2008/051365 WO2008095908A1 (en) 2007-02-06 2008-02-04 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity

Publications (1)

Publication Number Publication Date
MX2009008425A true MX2009008425A (es) 2009-08-17

Family

ID=38226351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008425A MX2009008425A (es) 2007-02-06 2008-02-04 Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.

Country Status (13)

Country Link
US (1) US20100075963A1 (es)
EP (1) EP2118060B1 (es)
JP (1) JP2010517976A (es)
KR (1) KR20090116732A (es)
CN (1) CN101605759A (es)
AT (1) ATE483685T1 (es)
AU (1) AU2008212887A1 (es)
BR (1) BRPI0807836A2 (es)
CA (1) CA2676145A1 (es)
DE (1) DE602008002901D1 (es)
EA (1) EA200901042A1 (es)
MX (1) MX2009008425A (es)
WO (1) WO2008095908A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2012172340A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating mental disorders
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
JP6249966B2 (ja) 2012-02-29 2017-12-20 ケモセントリックス， インコーポレイテッド アザ−アリール１ｈ−ピラゾール−１−イルベンゼンスルホンアミド
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
UY35165A (es) 2012-12-04 2014-06-30 Takeda Pharmaceutical Método profiláctico o terapéutico para el síndrome de sjogren
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
CN108698991B (zh) * 2016-01-20 2022-08-23 凯莫森特里克斯股份有限公司 2-氧代吲哚化合物
US11492341B2 (en) 2018-11-16 2022-11-08 Nimbus Artemis, Inc. ACLY inhibitors and uses thereof
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
KR20250146037A (ko) * 2024-03-29 2025-10-13 대원제약주식회사 헤테로이중고리 유도체 및 이를 포함하는 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DE60314175T2 (de) * 2002-11-18 2008-01-24 Chemocentryx Inc., Mountain View Arylsulfonamide

Also Published As

Publication number Publication date
WO2008095908A1 (en) 2008-08-14
BRPI0807836A2 (pt) 2014-08-05
US20100075963A1 (en) 2010-03-25
EP2118060A1 (en) 2009-11-18
EA200901042A1 (ru) 2010-02-26
KR20090116732A (ko) 2009-11-11
CN101605759A (zh) 2009-12-16
DE602008002901D1 (de) 2010-11-18
ATE483685T1 (de) 2010-10-15
CA2676145A1 (en) 2008-08-14
EP2118060B1 (en) 2010-10-06
JP2010517976A (ja) 2010-05-27
AU2008212887A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
MX2009008425A (es) Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
ATE453670T1 (de) Acrylierte hyaluronsäure
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200942545A (en) Azetidine and cyclobutane derivatives as JAK inhibitors
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MY151246A (en) Benzofuranyl derivatives
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
IN2012DN02471A (es)
EP2004188A4 (en) BENZOIMIDAZOLE-2-YL PYRIDINES AS HISTAMINE H4 RECEPTOR MODULATORS
TW200611904A (en) Aza-bicyclononanes
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
JO2645B1 (en) Vehicles
WO2012125981A3 (en) Raf kinase inhibitors
PH12012501389A1 (en) Hedgehog inhibitors
CU20110215A7 (es) Piperidinas sustituidas
WO2009115252A3 (de) Substituierte pyrazolamide und ihre verwendung
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
NO20092134L (no) Kombinasjonsprodukt for bruk i behandling av inflammatoriske lidelser
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration